Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study
Lung cancer screening with low-dose chest CT (LDCT) reduces the mortality of eligible individuals. Blood signatures might act as a standalone screening tool, refine the selection of patients at risk, or help to classify undetermined nodules detected on LDCT. We previously showed that circulating tum...
Gespeichert in:
| Veröffentlicht in: | The lancet respiratory medicine Jg. 8; H. 7; S. 709 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
01.07.2020
|
| ISSN: | 2213-2619, 2213-2619 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Lung cancer screening with low-dose chest CT (LDCT) reduces the mortality of eligible individuals. Blood signatures might act as a standalone screening tool, refine the selection of patients at risk, or help to classify undetermined nodules detected on LDCT. We previously showed that circulating tumour cells (CTCs) could be detected, using the isolation by size of epithelial tumour cell technique (ISET), long before the cancer was diagnosed radiologically. We aimed to test whether CTCs could be used as a biomarker for lung cancer screening.BACKGROUNDLung cancer screening with low-dose chest CT (LDCT) reduces the mortality of eligible individuals. Blood signatures might act as a standalone screening tool, refine the selection of patients at risk, or help to classify undetermined nodules detected on LDCT. We previously showed that circulating tumour cells (CTCs) could be detected, using the isolation by size of epithelial tumour cell technique (ISET), long before the cancer was diagnosed radiologically. We aimed to test whether CTCs could be used as a biomarker for lung cancer screening.We did a prospective, multicentre, cohort study in 21 French university centres. Participants had to be eligible for lung cancer screening as per National Lung Screening Trial criteria and have chronic obstructive pulmonary disease with a fixed airflow limitation defined as post-bronchodilator FEV1/FVC ratio of less than 0·7. Any cancer, other than basocellular skin carcinomas, detected within the previous 5 years was the main exclusion criterion. Participants had three screening rounds at 1-year intervals (T0 [baseline], T1, and T2), which involved LDCT, clinical examination, and a blood test for CTCs detection. Participants and investigators were masked to the results of CTC detection, and cytopathologists were masked to clinical and radiological findings. Our primary objective was to test the diagnostic performance of CTC detection using the ISET technique in lung cancer screening, compared with cancers diagnosed by final pathology, or follow up if pathology was unavailable as the gold standard. This study is registered with ClinicalTrials.gov identifier, number NCT02500693.METHODSWe did a prospective, multicentre, cohort study in 21 French university centres. Participants had to be eligible for lung cancer screening as per National Lung Screening Trial criteria and have chronic obstructive pulmonary disease with a fixed airflow limitation defined as post-bronchodilator FEV1/FVC ratio of less than 0·7. Any cancer, other than basocellular skin carcinomas, detected within the previous 5 years was the main exclusion criterion. Participants had three screening rounds at 1-year intervals (T0 [baseline], T1, and T2), which involved LDCT, clinical examination, and a blood test for CTCs detection. Participants and investigators were masked to the results of CTC detection, and cytopathologists were masked to clinical and radiological findings. Our primary objective was to test the diagnostic performance of CTC detection using the ISET technique in lung cancer screening, compared with cancers diagnosed by final pathology, or follow up if pathology was unavailable as the gold standard. This study is registered with ClinicalTrials.gov identifier, number NCT02500693.Between Oct 30, 2015, and Feb 2, 2017, we enrolled 614 participants, predominantly men (437 [71%]), aged 65·1 years (SD 6·5), and heavy smokers (52·7 pack-years [SD 21·5]). 81 (13%) participants dropped out between baseline and T1, and 56 (11%) did between T1 and T2. Nodules were detected on 178 (29%) of 614 baseline LDCTs. 19 participants (3%) were diagnosed with a prevalent lung cancer at T0 and 19 were diagnosed with incident lung cancer (15 (3%) of 533 at T1 and four (1%) of 477 at T2). Extrapulmonary cancers were diagnosed in 27 (4%) of participants. Overall 28 (2%) of 1187 blood samples were not analysable. At baseline, the sensitivity of CTC detection for lung cancer detection was 26·3% (95% CI 11·8-48·8). ISET was unable to predict lung cancer or extrapulmonary cancer development.FINDINGSBetween Oct 30, 2015, and Feb 2, 2017, we enrolled 614 participants, predominantly men (437 [71%]), aged 65·1 years (SD 6·5), and heavy smokers (52·7 pack-years [SD 21·5]). 81 (13%) participants dropped out between baseline and T1, and 56 (11%) did between T1 and T2. Nodules were detected on 178 (29%) of 614 baseline LDCTs. 19 participants (3%) were diagnosed with a prevalent lung cancer at T0 and 19 were diagnosed with incident lung cancer (15 (3%) of 533 at T1 and four (1%) of 477 at T2). Extrapulmonary cancers were diagnosed in 27 (4%) of participants. Overall 28 (2%) of 1187 blood samples were not analysable. At baseline, the sensitivity of CTC detection for lung cancer detection was 26·3% (95% CI 11·8-48·8). ISET was unable to predict lung cancer or extrapulmonary cancer development.CTC detection using ISET is not suitable for lung cancer screening.INTERPRETATIONCTC detection using ISET is not suitable for lung cancer screening.French Government, Conseil Départemental 06, Fondation UNICE, Fondation Aveni, Fondation de France, Ligue Contre le Cancer-Comité des Alpes-Maritimes, ARC (Canc'Air Genexposomics), Claire de Divonne-Pollner, Enca Faidhi, Basil Faidhi, Fabienne Mourou, Michel Mourou, Leonid Fridlyand, cogs4cancer, and the Fondation Masikini.FUNDINGFrench Government, Conseil Départemental 06, Fondation UNICE, Fondation Aveni, Fondation de France, Ligue Contre le Cancer-Comité des Alpes-Maritimes, ARC (Canc'Air Genexposomics), Claire de Divonne-Pollner, Enca Faidhi, Basil Faidhi, Fabienne Mourou, Michel Mourou, Leonid Fridlyand, cogs4cancer, and the Fondation Masikini. |
|---|---|
| AbstractList | Lung cancer screening with low-dose chest CT (LDCT) reduces the mortality of eligible individuals. Blood signatures might act as a standalone screening tool, refine the selection of patients at risk, or help to classify undetermined nodules detected on LDCT. We previously showed that circulating tumour cells (CTCs) could be detected, using the isolation by size of epithelial tumour cell technique (ISET), long before the cancer was diagnosed radiologically. We aimed to test whether CTCs could be used as a biomarker for lung cancer screening.BACKGROUNDLung cancer screening with low-dose chest CT (LDCT) reduces the mortality of eligible individuals. Blood signatures might act as a standalone screening tool, refine the selection of patients at risk, or help to classify undetermined nodules detected on LDCT. We previously showed that circulating tumour cells (CTCs) could be detected, using the isolation by size of epithelial tumour cell technique (ISET), long before the cancer was diagnosed radiologically. We aimed to test whether CTCs could be used as a biomarker for lung cancer screening.We did a prospective, multicentre, cohort study in 21 French university centres. Participants had to be eligible for lung cancer screening as per National Lung Screening Trial criteria and have chronic obstructive pulmonary disease with a fixed airflow limitation defined as post-bronchodilator FEV1/FVC ratio of less than 0·7. Any cancer, other than basocellular skin carcinomas, detected within the previous 5 years was the main exclusion criterion. Participants had three screening rounds at 1-year intervals (T0 [baseline], T1, and T2), which involved LDCT, clinical examination, and a blood test for CTCs detection. Participants and investigators were masked to the results of CTC detection, and cytopathologists were masked to clinical and radiological findings. Our primary objective was to test the diagnostic performance of CTC detection using the ISET technique in lung cancer screening, compared with cancers diagnosed by final pathology, or follow up if pathology was unavailable as the gold standard. This study is registered with ClinicalTrials.gov identifier, number NCT02500693.METHODSWe did a prospective, multicentre, cohort study in 21 French university centres. Participants had to be eligible for lung cancer screening as per National Lung Screening Trial criteria and have chronic obstructive pulmonary disease with a fixed airflow limitation defined as post-bronchodilator FEV1/FVC ratio of less than 0·7. Any cancer, other than basocellular skin carcinomas, detected within the previous 5 years was the main exclusion criterion. Participants had three screening rounds at 1-year intervals (T0 [baseline], T1, and T2), which involved LDCT, clinical examination, and a blood test for CTCs detection. Participants and investigators were masked to the results of CTC detection, and cytopathologists were masked to clinical and radiological findings. Our primary objective was to test the diagnostic performance of CTC detection using the ISET technique in lung cancer screening, compared with cancers diagnosed by final pathology, or follow up if pathology was unavailable as the gold standard. This study is registered with ClinicalTrials.gov identifier, number NCT02500693.Between Oct 30, 2015, and Feb 2, 2017, we enrolled 614 participants, predominantly men (437 [71%]), aged 65·1 years (SD 6·5), and heavy smokers (52·7 pack-years [SD 21·5]). 81 (13%) participants dropped out between baseline and T1, and 56 (11%) did between T1 and T2. Nodules were detected on 178 (29%) of 614 baseline LDCTs. 19 participants (3%) were diagnosed with a prevalent lung cancer at T0 and 19 were diagnosed with incident lung cancer (15 (3%) of 533 at T1 and four (1%) of 477 at T2). Extrapulmonary cancers were diagnosed in 27 (4%) of participants. Overall 28 (2%) of 1187 blood samples were not analysable. At baseline, the sensitivity of CTC detection for lung cancer detection was 26·3% (95% CI 11·8-48·8). ISET was unable to predict lung cancer or extrapulmonary cancer development.FINDINGSBetween Oct 30, 2015, and Feb 2, 2017, we enrolled 614 participants, predominantly men (437 [71%]), aged 65·1 years (SD 6·5), and heavy smokers (52·7 pack-years [SD 21·5]). 81 (13%) participants dropped out between baseline and T1, and 56 (11%) did between T1 and T2. Nodules were detected on 178 (29%) of 614 baseline LDCTs. 19 participants (3%) were diagnosed with a prevalent lung cancer at T0 and 19 were diagnosed with incident lung cancer (15 (3%) of 533 at T1 and four (1%) of 477 at T2). Extrapulmonary cancers were diagnosed in 27 (4%) of participants. Overall 28 (2%) of 1187 blood samples were not analysable. At baseline, the sensitivity of CTC detection for lung cancer detection was 26·3% (95% CI 11·8-48·8). ISET was unable to predict lung cancer or extrapulmonary cancer development.CTC detection using ISET is not suitable for lung cancer screening.INTERPRETATIONCTC detection using ISET is not suitable for lung cancer screening.French Government, Conseil Départemental 06, Fondation UNICE, Fondation Aveni, Fondation de France, Ligue Contre le Cancer-Comité des Alpes-Maritimes, ARC (Canc'Air Genexposomics), Claire de Divonne-Pollner, Enca Faidhi, Basil Faidhi, Fabienne Mourou, Michel Mourou, Leonid Fridlyand, cogs4cancer, and the Fondation Masikini.FUNDINGFrench Government, Conseil Départemental 06, Fondation UNICE, Fondation Aveni, Fondation de France, Ligue Contre le Cancer-Comité des Alpes-Maritimes, ARC (Canc'Air Genexposomics), Claire de Divonne-Pollner, Enca Faidhi, Basil Faidhi, Fabienne Mourou, Michel Mourou, Leonid Fridlyand, cogs4cancer, and the Fondation Masikini. |
| Author | Marquette, Charles-Hugo Boutros, Jacques Pastre, Jean Fallet, Vincent Hofman, Véronique Benzaquen, Jonathan Ferreira, Marion Ilie, Marius Padovani, Bernard Hofman, Paul Pison, Christophe Guibert, Nicolas Bettayeb, Faiza Basille, Damien |
| Author_xml | – sequence: 1 givenname: Charles-Hugo surname: Marquette fullname: Marquette, Charles-Hugo – sequence: 2 givenname: Jacques surname: Boutros fullname: Boutros, Jacques – sequence: 3 givenname: Jonathan surname: Benzaquen fullname: Benzaquen, Jonathan – sequence: 4 givenname: Marion surname: Ferreira fullname: Ferreira, Marion – sequence: 5 givenname: Jean surname: Pastre fullname: Pastre, Jean – sequence: 6 givenname: Christophe surname: Pison fullname: Pison, Christophe – sequence: 7 givenname: Bernard surname: Padovani fullname: Padovani, Bernard – sequence: 8 givenname: Faiza surname: Bettayeb fullname: Bettayeb, Faiza – sequence: 9 givenname: Vincent surname: Fallet fullname: Fallet, Vincent – sequence: 10 givenname: Nicolas surname: Guibert fullname: Guibert, Nicolas – sequence: 11 givenname: Damien surname: Basille fullname: Basille, Damien – sequence: 12 givenname: Marius surname: Ilie fullname: Ilie, Marius – sequence: 13 givenname: Véronique surname: Hofman fullname: Hofman, Véronique – sequence: 14 givenname: Paul surname: Hofman fullname: Hofman, Paul |
| BookMark | eNpNT01LAzEQDVLBWvsThBzrYTWZze4m3qRYFQoe1HNJp7N1dZvUfAj-e7fYg4-B-eC9x7xzNnLeEWOXUlxLIeubFwBZFlALMQNxVQqhZVGesPHxLM3o33zGpjF-iAFaKxBqzLbzLmDuberclqe88zlwpL6P3A7F9z6RS53t-brzOxs-KfDWB97ngY7W4bBHDERu0N8eBMHHPWHqvomjf_ch8Zjy5ueCnba2jzQ99gl7W9y_zh-L5fPD0_xuWaBqmlRIVBUioabWGIUWGkJjgCpaS62UbhRVQrWiNY1uStyAbGUljKms1JK0hQmb_fkOj3xlimm16-IhkHXkc1yBglLUGrSBX8iPX0o |
| CitedBy_id | crossref_primary_10_1016_j_bbcan_2022_188729 crossref_primary_10_2147_LCTT_S388047 crossref_primary_10_1016_j_lungcan_2021_04_014 crossref_primary_10_3390_cells11182871 crossref_primary_10_3390_jpm13040694 crossref_primary_10_1002_1878_0261_13099 crossref_primary_10_3390_cancers13092049 crossref_primary_10_3389_fimmu_2022_966661 crossref_primary_10_1016_S2213_2600_20_30115_6 crossref_primary_10_1016_j_tranon_2023_101735 crossref_primary_10_1002_smtd_202300055 crossref_primary_10_1177_09691413221117685 crossref_primary_10_1016_j_canlet_2024_217216 crossref_primary_10_1016_j_jtho_2023_08_019 crossref_primary_10_1038_s41596_023_00943_3 crossref_primary_10_1016_j_lungcan_2024_107952 crossref_primary_10_1002_advs_202417849 crossref_primary_10_3390_jcm9123860 crossref_primary_10_1093_carcin_bgab119 crossref_primary_10_1186_s12014_022_09376_8 crossref_primary_10_1016_j_mbm_2023_100014 crossref_primary_10_3390_cells9112486 crossref_primary_10_1016_j_jtho_2023_07_005 crossref_primary_10_1007_s12032_024_02489_0 crossref_primary_10_1016_j_apsb_2022_01_005 crossref_primary_10_3390_cancers13205149 crossref_primary_10_1016_j_prp_2023_154455 crossref_primary_10_1038_s41571_023_00781_y crossref_primary_10_1016_j_tips_2022_02_005 crossref_primary_10_1159_000538434 crossref_primary_10_1038_s41467_024_50150_1 crossref_primary_10_3390_cancers13163923 crossref_primary_10_1016_j_critrevonc_2024_104483 crossref_primary_10_1177_02184923231215538 crossref_primary_10_1245_s10434_023_14168_x crossref_primary_10_1016_j_clon_2024_07_004 crossref_primary_10_1158_2159_8290_CD_20_1311 crossref_primary_10_1002_cncy_22367 crossref_primary_10_1007_s12094_024_03556_8 crossref_primary_10_1158_2159_8290_CD_20_0466 crossref_primary_10_1016_j_jtho_2022_10_002 crossref_primary_10_1183_13993003_04367_2020 crossref_primary_10_1016_j_lungcan_2024_107829 crossref_primary_10_1016_j_snb_2024_135421 crossref_primary_10_3389_fonc_2022_853801 crossref_primary_10_1016_j_annonc_2022_01_008 crossref_primary_10_3390_cancers13174488 crossref_primary_10_3390_jor5030011 crossref_primary_10_1007_s44178_023_00066_5 crossref_primary_10_3390_cancers16111980 crossref_primary_10_1136_bmjopen_2023_074680 crossref_primary_10_1007_s00281_025_01042_z crossref_primary_10_3390_cancers13133294 crossref_primary_10_1177_17588359231167818 crossref_primary_10_3389_fonc_2022_859152 crossref_primary_10_1016_j_canlet_2021_10_013 crossref_primary_10_1177_11795549241231568 crossref_primary_10_3390_cancers13153919 crossref_primary_10_3390_jmp2030021 crossref_primary_10_3390_cancers12113192 crossref_primary_10_1007_s00432_021_03852_8 crossref_primary_10_1007_s12672_024_00976_4 crossref_primary_10_1016_j_chest_2023_05_025 crossref_primary_10_1016_j_lungcan_2023_107262 crossref_primary_10_1016_j_microc_2025_114907 crossref_primary_10_1038_s41572_024_00551_9 crossref_primary_10_1038_s41598_023_35818_w crossref_primary_10_1002_1878_0261_12869 crossref_primary_10_1080_14737159_2021_1985468 crossref_primary_10_1016_j_neo_2024_101006 crossref_primary_10_3389_fcell_2024_1498032 crossref_primary_10_1016_j_jtho_2025_01_021 crossref_primary_10_1002_1878_0261_12864 crossref_primary_10_1016_j_cej_2025_162155 crossref_primary_10_1186_s40364_022_00403_2 crossref_primary_10_3389_fonc_2024_1474015 |
| ContentType | Journal Article |
| Copyright | Copyright © 2020 Elsevier Ltd. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2020 Elsevier Ltd. All rights reserved. |
| DBID | 7X8 |
| DOI | 10.1016/S2213-2600(20)30081-3 |
| DatabaseName | MEDLINE - Academic |
| DatabaseTitle | MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2213-2619 |
| GroupedDBID | .1- .FO 0R~ 1P~ 4.4 457 53G 7X8 AAEDT AAEDW AALRI AAMRU AAQFI AAXUO ABJNI ACGFS ADBBV AENEX AFRHN AFTJW AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP EBS EFKBS FDB M41 O9- OI- OU. ROL TLN Z5R |
| ID | FETCH-LOGICAL-c477t-1c45ccec8ef994ca27ec992e5eb1844874e504f0f97873cd21f150995a181e8a2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 98 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000547326600023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2213-2619 |
| IngestDate | Mon Sep 29 04:35:18 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c477t-1c45ccec8ef994ca27ec992e5eb1844874e504f0f97873cd21f150995a181e8a2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://hal.science/hal-02897076 |
| PQID | 2423068289 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2423068289 |
| PublicationCentury | 2000 |
| PublicationDate | 20200701 |
| PublicationDateYYYYMMDD | 2020-07-01 |
| PublicationDate_xml | – month: 07 year: 2020 text: 20200701 day: 01 |
| PublicationDecade | 2020 |
| PublicationTitle | The lancet respiratory medicine |
| PublicationYear | 2020 |
| SSID | ssj0000884204 |
| Score | 2.560912 |
| Snippet | Lung cancer screening with low-dose chest CT (LDCT) reduces the mortality of eligible individuals. Blood signatures might act as a standalone screening tool,... |
| SourceID | proquest |
| SourceType | Aggregation Database |
| StartPage | 709 |
| Title | Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study |
| URI | https://www.proquest.com/docview/2423068289 |
| Volume | 8 |
| WOSCitedRecordID | wos000547326600023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NS8QwEA3qinjxW_wmggc9hG2TZpN6EVlcvLgIKuxtSdNkWZB2bbv-fmdi1z14EYSeSlPaYTLz3mSSR8gVQhDIZDEDZ8gYIGLFMpHDdE8h-yuTc8_zIDahhkM9GqXPbcGtbtsqFzExBOq8tFgj72Lej3rID-5mHwxVo3B1tZXQWCUdAVAGvVqN9E-NBWZQwoOCIOexYEgWlpt4ui_tzSi65tGNwOTIxK-QHPLMYPu_X7hDtlqESe-_XWKXrLhij2w8tWvo-2TSn1Y2iHYVE9rMgfpXFMv3NTVw0VnZYAMRvAF35mPzTkUB2NJ3iArUoo9UFEIN0F8Yf4sDqnKxXZOi3G7V0HBm7QF5Gzy89h9ZK7fAbKJUw2KbSGud1c6naWINV86mKXcSwrkGFqcSJ6PERx6IpxI257EHNJmm0gBKcNrwQ7JWlIU7ItRwK2LpM-m1TzIntZFZpC1YR4qeMPqYXC5MOAZ3xp80hSvn9XhpxJM_PHNKNjny39A-e0Y6HqasOyfr9rOZ1tVF8IYvWJy9Ug |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Circulating+tumour+cells+as+a+potential+biomarker+for+lung+cancer+screening%3A+a+prospective+cohort+study&rft.jtitle=The+lancet+respiratory+medicine&rft.au=Marquette%2C+Charles-Hugo&rft.au=Boutros%2C+Jacques&rft.au=Benzaquen%2C+Jonathan&rft.au=Ferreira%2C+Marion&rft.date=2020-07-01&rft.issn=2213-2619&rft.eissn=2213-2619&rft.volume=8&rft.issue=7&rft.spage=709&rft_id=info:doi/10.1016%2FS2213-2600%2820%2930081-3&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2213-2619&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2213-2619&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2213-2619&client=summon |